Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus

Journal of Neurology Neurosurgery and Psychiatry

Volumn 65, Issue 2, 1998, Pages 204-208

  Hummel, M ^a   Durinovic Bello, I ^a   Bonifacio, E ^b   Lampasona, V ^b   Endl, J ^c   Fessele, S ^c   Then Bergh, F ^d   Trenkwalder, C ^d   Standl, E ^a   Ziegler, A G ^a,e  

^a Klinikum Schwabing   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

Author keywords

Autoantibodies; Prednisolone therapy; Stiff man syndrome; T cell reactivity

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CORTISONE; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; CYTOKINE RELEASE; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; STIFF MAN SYNDROME; T LYMPHOCYTE;

EID: 0031874058     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.65.2.204     Document Type: Article

References (28)

1. Toro C, Jacobowitz DM, Hallett M. Stiff-man syndrome. Semin Neurol 1994;14:154-8.
2. Sander JE, Layzer RB, Goldsobel AB. Congenital stiff-man syndrome. Ann Neurol 1980;8:195-7.
3. Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kDa synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328:546-51.
4. De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993;178:2219-23.
5. Layzer RB. Stiff-man syndrome - an autoimmune disease? N Engl J Med 1988;318:1060-1.
6. Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurones and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990;322:1555-60.
7. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamatic acid decarboxylase. Nature 1990;347:151-6.
8. Vicari AM, Folli F, Pozza G, et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med 1989;320: 1499.
9. Butler MH, Solimena M, Dirkx R Jr, et al. Identification of a dominant epitope of glutamatic acid decarboxylase (GAD65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993;178:2097-106.
10. Christie MR, Genovese S, Cassidy D, et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994;43:1254-9.
11. Martino G, Grimaldi GM, Bazzigaluppi E, et al. The insulin-dependent diabetes mellitus-associated ICA 105 autoantigen in stiff-man syndrome patients. J Neuroimmunol 1996;69:129-34.
12. Hummel M, Durinovic-Bello I, Ziegler AG. Relation between cellular and humoral immune response to diverse islet-cell antigens in IDDM. J Autoimmun 1996;9:427-30.
13. Lorish TR, Thorsteinsson G, Howard FM. Stiff-man syndrome updated. Mayo Clin Proc 1989;74:729-37.
14. Roll U, Christie MR, Füchtenbusch M, et al. Perinatal autoimmunity in offspring of diabetic parents. The German multicenter BABY-DIAB study: detection of humoral immune response to islet antigens in early childhood. Diabetes 1996;45:926-33.
15. Ziegler AG, Ziegler R, Vardi P, et al. Lifetable analysis of progression to diabetes of anti-insulin autoantibody positive relatives of individuals with type 1 diabetes. Diabetes 1989;38:1320-5.
16. Falorni A, Ackefors M, Carlberg C, et al. Diagnostic sensitivity of immunodominant epitopes of glutamatic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia 1996;39:1091-8.
17. Nemni R, Braghi S, Natali-Sora MG, et al. Autoantibodies to glutamatic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 1994;36:665-7.
18. Bonifacio E, Genovese S, Braghi S, et al. Isle T autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetolagia 1995;38:816-22.
19. Bonifacio E, Lamposona V, Genovese S, et al. Identification of protein tyrosine phosphatase-like IA2 (isleT-cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of isleT-cell antibodies. J Immunol 1995;155:5419-26.
20. Durinovic-Bello I, Hummel M, Ziegler AG. Cellular immune response to diverse isle T-cell antigens in IDDM. Diabetes 1996;45:795-800.
21. r tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995;96:1506-11,
22. Piccolo G, Cosi V, Zandrini C, et al. Steroid-responsive and dependent stiff-man syndrome: a clinical and electrophysiologic study in two cases. Ital J Neurol Sci 1988;9:559-77.
23. Harding AE, Thompson PD, Kocen RS, et al. Plasma exchange and immunosuppression in the sifff-man syndrome. Lancet 1989;ii:915.
24. Ellis TM, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med 1996;2:148-53.
25. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune diseases. Ann Rev Immunol 1993;11:79-104.
26. Brinkmann V, Kristofic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. J Imnnmol 1995;155:3322-8.
27. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-42.
28. Mellon SH. Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab 1994;78: 1003-8.